8-K

                          UNITED STATES
               SECURITIES AND EXCHANGE COMMISSION
                     Washington, D. C. 20549



                            FORM 8-K

                         Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
                              1934



Date of Report (Date of earliest event reported):  April 8, 2003



                      HEMACARE CORPORATION
     (Exact name of registrant as specified in its charter)



                           CALIFORNIA
         (State or other jurisdiction of incorporation)



           000-15223                        95-3280412
     (Commission File No.)       (IRS Employer Identification No.)



                       21101 Oxnard Street
                    Woodland Hills, CA 91367
      (Address of principal executive offices and Zip Code)



Registrant's telephone number, including area code: (818) 226-1968




ITEM 7.   FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMAITON
          AND EXHIBITS

          (c) Exhibits

          Exhibit Number Description
          -------------- ---------------------------------------------

          99.1           Press Release issued by HemaCare Corporation,
                         dated April 8, 2003


ITEM 9.   REGULATION FD DISCLOSURE

          The text of a press release dated April 8, 2003, issued by
          HemaCare Corporation ("HemaCare")  regarding the development
          of a new liquid intravenous gamma globulin (IVIG) manufacturing
          process is attached as Exhibit 99.1 hereto and is incorporated
          by reference herein.  However, there can be no assurance that
          HemaCare will be successful in obtaining a U.S. patent for the
          IVIG manufacturing process or that HemaCare will be able to
          license this process to commercial fractionators.


                           SIGNATURES

Pursuant  to the requirements of the Securities Exchange  Act  of
1934, the registrant has duly caused this report to be signed  on
its behalf by the undersigned hereunto duly authorized.



Date: April 8, 2003          HEMACARE CORPORATION


                             /s/ Judi Irving
                             --------------------------
                              Judi Irving,
                              Chief Executive Officer




                          EXHIBIT INDEX

Exhibit Number      Description
- --------------      ----------------------------------------------
99.1                Press Release issued by HemaCare Corporation,
                    dated April 8, 2003.

EX-99.1 CHARTER

                        LOGO

              N E W S   R E L E A S E

For Immediate Release

Contact:       HemaCare Corporation
          JoAnn Stover, Director of Investor Relations
          877-310-0717
          www.hemacare.com

RELEASE DATE:  April 8, 2003

           HEMACARE CORPORATION ANNOUNCES THE DEVELOPMENT
               OF A LIQUID IVIG MANUFACTURING PROCESS

     LOS  ANGELES  ------ HemaCare Corporation (OTC  Bulletin  Board:
HEMA)  announced  today that it has developed  a  liquid  intravenous
immune  globulin  ("IVIG")  manufacturing  process,  which  is   used
primarily  in the treatment of immune deficiencies.  Immune  globulin
is  a  protein  fractionated  from human plasma.   The  manufacturing
process  offers an approximate 75% yield from plasma (as compared  to
approximately  45% with most current methods), with high  purity  and
extremely  low  IgA levels. In addition, this process involves  fewer
steps  than  conventional IVIG purification methods,  shortening  the
production cycle and reducing costs.  The Company stated that it  has
submitted  a U.S. patent application for this method and will  pursue
licensing the process to commercial fractionators. Commercial benefit
to  HemaCare  in  the  future  is dependent  on  obtaining  licensing
agreements with plasma fractionators.

     The  IVIG  fractionation industry has a market of  approximately
$500 million world-wide. Immune globulin, a protein fractionated from
human   plasma,  is  used  primarily  in  the  treatment  of   immune
deficiencies  and,  in high dose, as a treatment  for  a  variety  of
autoimmune  diseases including disorders in the fields  of  neurology
and hematology.

                     About HemaCare Corporation

     Founded  in  1978,  HemaCare  is a national  provider  of  blood
products and services and the only publicly traded company engaged in
the  blood services industry in the U.S.  HemaCare is licensed by the
FDA  and accredited by the American Association of Blood Banks.   The
Company  focuses on providing cost effective, high quality  solutions
to the blood-related needs of U.S. hospitals.


This  press release contains "forward-looking statements" within  the
meaning  of the term in the Private Securities Litigation Reform  Act
of  1995 (Section 27A of the Securities Act of 1933, as amended,  and
Section  21E  of  the Securities Exchange Act of 1934,  as  amended).
Additional written or oral forward-looking statements may be made  by
the  Company  from  time to time in filings with the  Securities  and
Exchange  Commission or otherwise.  Statements contained herein  that
are  not historical facts are forward-looking statements pursuant  to
the   safe   harbor  provisions  referenced  above.   Forward-looking
statements are inherently subject to risks and uncertainties some  of
which   cannot   be  predicted  or  quantified.    Such   risks   and
uncertainties   include,   without   limitation,   the   risks    and
uncertainties  set forth from time to time in reports  filed  by  the
Company  with  the Securities and Exchange Commission.  Although  the
Company  believes  that the expectations reflected in  such  forward-
looking statements are reasonable, it can give no assurance that such
expectations  will prove to have been correct.  Consequently,  future
events  and  actual results could differ materially  from  those  set
forth   in,  contemplated  by,  or  underlined  the  forward  looking
statements contained herein.  The Company undertakes no obligation to
publicly  release  any revision to these forward  looking  statements
made to reflect events or circumstances after the date hereof.

                                 ###